Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.52 |
| ▸ | IGF1R | P08069 | 6/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 6/20 | 0.49 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.46 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL529618 | 0.86 | ESR1 (0.68) | ESR1ESR2IGF1RALOX15SLC28A3 | |
| SCHEMBL28999062 | 0.82 | SLC28A3 (0.67) | ESR1ESR2IGF1RALOX15SLC28A3 | |
| SCHEMBL68664 | 0.82 | ESR1 (0.68) | ESR1ESR2IGF1RALOX15SLC28A3 | |
| SCHEMBL28386624 | 0.81 | IGF1R (0.65) | ESR1ESR2IGF1RALOX15SLC28A3 | |
| SCHEMBL5569448 | 0.81 | BACE1 (0.57) | ESR1ESR2IGF1RALOX15SLC28A3 | |
| SCHEMBL2475751 | 0.80 | NPC1 (0.62) | ESR1ESR2IGF1RALOX15SKP2 | |
| SCHEMBL12949979 | 0.80 | ESR1 (0.65) | ESR1ESR2IGF1RALOX15SLC28A3 | |
| SCHEMBL8402779 | 0.80 | ESR1 (0.65) | ESR1ESR2IGF1RALOX15SLC28A3 | |
| SCHEMBL16065724 | 0.80 | ESR1 (0.65) | ESR1ESR2IGF1RALOX15SLC28A3 | |
| SCHEMBL6227927 | 0.80 | ESR1 (0.65) | ESR1ESR2IGF1RALOX15SLC28A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7312249-B2 | Vitamin D analogues | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-12-25 | — | — | US | disclosed |
| EP-1537065-B1 | ANALOGUES OF VITAMIN D | GALDERMA RES & DEV (FR) | 2006-11-02 | — | — | EP | disclosed |
| US-20050182144-A1 | Novel vitamin D analogues | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-08-18 | — | — | US | disclosed |
| EP-1537065-A1 | ANALOGUES OF VITAMIN D | Galderma Research & Development, S.N.C. (FR) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004020379-A1 | ANALOGUES OF VITAMIN D | GALDERMA RESEARCH & DEVELOPMENT, SNC (FR) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182144-A1 | Novel vitamin D analogues | CYP24A1, CYP2R1, VDR | ESR1 1406/4885ESR2 851/4885IGF1R 1383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.